Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density-Reference-Cited by-同舟云学术

Genetic polymorphisms in the mevalonate pathway affect the therapeutic response to alendronate treatment in postmenopausal Chinese women with low bone mineral density

Published:2014-09-16 Issue:2 Volume:15 Page:158-164
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Wang C,Zheng H,He J-W,Zhang H,Yue H,Hu W-W,Gu J-M,Shao C,Fu W-Z,Hu Y-Q,Li M,Liu Y-J,Zhang Z-L

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology,Genetics,Molecular Medicine

Link

http://www.nature.com/articles/tpj201452.pdf

Reference39 articles.

1. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd . The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int 2012; 23: 811–820.

2. Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M et al. Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 2012; 27: 125–129.

3. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399–428.

4. Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 1802–1822.

5. Ogawa S, Ouchi Y . [Therapeutic purpose and treatment guideline of osteoporosis]. Clin Calcium 2012; 22: 885–889.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Farnesyl Diphosphate Synthase Gene Associated with Loss of Bone Mass Density and Alendronate Treatment Failure in Patients with Primary Osteoporosis;International Journal of Molecular Sciences;2024-05-22

2. The Change in Body Temperature, Not Acute-Phase Reaction, Predicts anit-Osteoporosis Efficacy after the First Administration of Zoledronic Acid in a self-control study;2024-04-05

3. Association Between CTSK Gene Polymorphisms and Response to Alendronate Treatment in Postmenopausal Chinese Women with Low Bone Mineral Density;Pharmacogenomics and Personalized Medicine;2023-10

4. Identifying therapeutic biomarkers of zoledronic acid by metabolomics;Frontiers in Pharmacology;2023-04-25

5. Genetic Polymorphisms of Nuclear Factor-κB Family Affect the Bone Mineral Density Response to Zoledronic Acid Therapy in Postmenopausal Chinese Women;Genes;2022-07-27